RxDoctor Payments Data

Toniya Singh, MD

Cardiovascular Disease · Saint Louis, MONPI 1629082847

Payments from drug & device makers

$21,923in general payments, 2019–2025

Across 622 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Novartis$2K
  • Johnson & Johnson$729
  • Boehringer Ingelheim$639
  • Pfizer$582
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$3,01914%
  • Speaking & faculty fees$8,00036%
  • Travel & lodging$7784%
  • Food & beverage$9,99846%
  • Education$1281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,923 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$403,515
Medicare patients
741
Services billed
4,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban418$460,577
XareltoRivaroxaban207$260,155
EntrestoSacubitril/Valsartan161$195,397
JardianceEmpagliflozin126$136,472
FarxigaDapagliflozin Propanediol109$107,249
OzempicSemaglutide86$92,406
MounjaroTirzepatide41$51,018
WegovySemaglutide23$37,744
Repatha SureclickEvolocumab39$27,032
BrilintaTicagrelor16$19,706
Ranolazine ErRanolazine177$19,017
Praluent PenAlirocumab12$15,085
VascepaIcosapent Ethyl18$13,108
NexletolBempedoic Acid11$12,529
Metoprolol Succinate619$6,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$582$460,577418 claims
Johnson & JohnsonXarelto$729$260,155207 claims
NovartisEntresto$2,077$195,397161 claims
Boehringer IngelheimJardiance$639$136,472126 claims
Novo NordiskOzempic, Wegovy$98$130,150109 claims
AstraZenecaFarxiga, Brilinta$486$126,956125 claims
Lilly USA, LLCMounjaro$137$51,01841 claims
Esperion Therapeutics, Inc.Nexletol$359$12,52911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →